CA2214143A1 - Combination compositions containing benazepril or benazeprilat and valsartan - Google Patents

Combination compositions containing benazepril or benazeprilat and valsartan Download PDF

Info

Publication number
CA2214143A1
CA2214143A1 CA002214143A CA2214143A CA2214143A1 CA 2214143 A1 CA2214143 A1 CA 2214143A1 CA 002214143 A CA002214143 A CA 002214143A CA 2214143 A CA2214143 A CA 2214143A CA 2214143 A1 CA2214143 A1 CA 2214143A1
Authority
CA
Canada
Prior art keywords
active ingredient
valsartan
composition according
ingredient component
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002214143A
Other languages
English (en)
French (fr)
Inventor
Marc De Gasparo
David Saul Cohen
Randy Lee Webb
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2214143A1 publication Critical patent/CA2214143A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002214143A 1995-04-07 1996-04-02 Combination compositions containing benazepril or benazeprilat and valsartan Abandoned CA2214143A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH1012/95 1995-04-07
CH101295 1995-04-07

Publications (1)

Publication Number Publication Date
CA2214143A1 true CA2214143A1 (en) 1996-10-10

Family

ID=4200393

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002214143A Abandoned CA2214143A1 (en) 1995-04-07 1996-04-02 Combination compositions containing benazepril or benazeprilat and valsartan

Country Status (15)

Country Link
EP (1) EP0820302A1 (hu)
JP (1) JPH11503139A (hu)
KR (1) KR19980703647A (hu)
CN (1) CN1181019A (hu)
AU (1) AU5399096A (hu)
BR (1) BR9604818A (hu)
CA (1) CA2214143A1 (hu)
CZ (1) CZ313897A3 (hu)
HU (1) HUP9801593A2 (hu)
MX (1) MX9707683A (hu)
NO (1) NO974400D0 (hu)
PL (1) PL322529A1 (hu)
SK (1) SK133897A3 (hu)
TR (1) TR199701121T1 (hu)
WO (1) WO1996031234A1 (hu)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11508894A (ja) * 1995-06-30 1999-08-03 メルク エンド カンパニー インコーポレーテッド Ａｃｅ阻害剤とａｉｉ拮抗薬を用いる腎疾患の治療方法
CN101011390A (zh) 1999-01-26 2007-08-08 诺瓦提斯公司 血管紧张素ⅱ受体拮抗剂在治疗急性心肌梗塞中的应用
AR032152A1 (es) * 2000-04-12 2003-10-29 Novartis Ag Uso de una combinacion de compuestos terapeuticos organicos para la fabricacion de un medicamento, un agente terapeutico, y una composicion farmaceutica
CA2415962C (en) * 2000-07-19 2010-07-06 Novartis Ag Valsartan salts
EP1671632A1 (en) * 2000-08-22 2006-06-21 Boehringer Ingelheim Pharma GmbH & Co. KG Pharmaceutical combination of angiotensin II antagonists and ACE inhibitors
GB0020691D0 (en) * 2000-08-22 2000-10-11 Boehringer Ingelheim Pharma Pharmaceutical combination
WO2002049645A1 (en) * 2000-12-18 2002-06-27 Novartis Ag Therapeutic combination of amlodipine and benazepril
US6869970B2 (en) * 2002-02-04 2005-03-22 Novartis Ag Crystalline salt forms of valsartan
CN100377744C (zh) * 2002-07-05 2008-04-02 安徽省生物医学研究所 一种预测acei类降压药药效的复方药
WO2004019876A2 (en) * 2002-08-28 2004-03-11 Curis, Inc. Conjoint administration of morphogens and ace inhibitors in treatment of chronic renal failure
EP1908469A1 (en) 2006-10-06 2008-04-09 Boehringer Ingelheim Vetmedica Gmbh Angiotensin II receptor antagonist for the treatment of systemic diseases in cats
CN101869710A (zh) * 2009-04-24 2010-10-27 北京奥萨医药研究中心有限公司 降压药物组合物
JP5612674B2 (ja) 2009-05-20 2014-10-22 ベーリンガー インゲルハイム フェトメディカ ゲゼルシャフト ミットベシュレンクテル ハフツング テルミサルタンを含む経口懸濁液
US20110009347A1 (en) 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
MX2016010011A (es) * 2014-01-31 2016-10-07 Janssen Pharmaceutica Nv Metodos para tratar y prevenir trastornos renales y trastornos del higado graso.

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE148632T1 (de) * 1990-05-11 1997-02-15 Pfizer Synergistische therapeutische zusammensetzungen und verfahren
EP0629408A1 (en) * 1993-06-16 1994-12-21 LABORATOIRES MERCK, SHARP & DOHME-CHIBRET Combination of angiotensin converting enzyme inhibitors and AII antagonists

Also Published As

Publication number Publication date
AU5399096A (en) 1996-10-23
BR9604818A (pt) 1998-06-09
MX9707683A (es) 1997-12-31
EP0820302A1 (en) 1998-01-28
CZ313897A3 (cs) 1998-01-14
NO974400L (no) 1997-09-23
PL322529A1 (en) 1998-02-02
WO1996031234A1 (en) 1996-10-10
JPH11503139A (ja) 1999-03-23
HUP9801593A2 (hu) 1999-01-28
CN1181019A (zh) 1998-05-06
KR19980703647A (ko) 1998-12-05
TR199701121T1 (xx) 1998-03-21
NO974400D0 (no) 1997-09-23
SK133897A3 (en) 1998-02-04

Similar Documents

Publication Publication Date Title
JP6373931B2 (ja) 循環器系疾患のためのレニン阻害剤を含む相乗的組合せ剤
EP2322174B1 (en) Combined use of valsartan and calcium channel blockers for therapeutic purposes
EP1467728B1 (en) Pharmaceutical compositions comprising valsartan and nep inhibitors
RU2316318C2 (ru) Фармацевтическая композиция, включающая ингибитор ренина, блокатор кальциевых каналов и диуретик
US8404744B2 (en) Methods of treatment and pharmaceutical composition
CA2214143A1 (en) Combination compositions containing benazepril or benazeprilat and valsartan
JP2005532330A5 (hu)
WO2007106708A2 (en) Combinations of the angiotensin ii antagonist valsartan and the nep inhibitor daglutril
Morganti et al. Aliskiren: the first direct renin inhibitor available for clinical use
EA009983B1 (ru) Лекарственное средство для профилактики и лечения артериосклероза и гипертензии
US20040259925A1 (en) Pharmaceutical compositions and methds for the prevention or treatment of cardiovascular, cardiopulmonary, pulmonary or renal diseases
CA2513281C (en) Pharmaceutical combination for the prevention or treatment of cardiovascular, cardiopulmonary, pulmonary or renal diseases
EP1146872B1 (en) Use of angiotensin ii receptor antagonists for treating acute myocardial infarction
US6767905B2 (en) Use of angiotensin II receptor antagonists for treating acute myocardial infarction
KR20230006884A (ko) 뇌 아미노펩티다제 a 억제제, 이뇨제, 및 전신 레닌-안지오텐신 시스템의 차단제를 포함하는 약학 병용물
Waeber et al. Antihypertensive Agents: Mechanisms of Drug Action
ZA200503809B (en) Pharmaceutical combination for the prophylaxis or treatment of cardiovascular, cardiopulmonary, pulmonary or renal diseases
AU2006202999A1 (en) Pharmaceutical compositions comprising valsartan and NEP inhibitors

Legal Events

Date Code Title Description
FZDE Discontinued